nach oben

Current Treatment Options in Neurology

Erschienen in:

18.05.2023

Diagnosis and Treatment of Inflammatory Cerebral Amyloid Angiopathy

verfasst von: Samuel S. Bruce, MD, MA, Neal S. Parikh, MD, MS

Erschienen in: Current Treatment Options in Neurology | Ausgabe 7/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

In this article, we discuss the current consensus approach to the evaluation and treatment of inflammatory cerebral amyloid angiopathy (CAA). We also outline critical knowledge gaps and identify questions for future research.

Recent findings

Recent cohort studies found that immunosuppressive treatment for inflammatory CAA was associated with higher probability of clinical and radiographic improvement and reduced risk of disease recurrence. A recent case series showed correlations between changes in cerebrospinal fluid levels of anti-Aβ autoantibodies, changes in microglial activation, and clinical and radiographic response to immunosuppressive treatment; these data provide supporting evidence for a pathophysiological link between inflammatory CAA and adverse events associated with Alzheimer’s disease (AD) immunotherapy treatments.

Summary

Despite many knowledge gaps, widely accepted methods for diagnosis and management of inflammatory CAA have emerged, including validated clinical and radiographic criteria and treatment with immunosuppressive medications. Still, there is considerable space for diagnosis and treatment paradigms to advance in tandem with our understanding of the disease. Efforts to optimize protocols for clinical and radiographic assessment, identify biomarkers at multiple stages of disease, and leverage insights from Alzheimer’s disease biomarkers and therapeutics will be pivotal to achieving these goals.

Kozberg MG, Perosa V, Gurol ME, van Veluw SJ. A practical approach to the management of cerebral amyloid angiopathy. Int J Stroke. 2021;16(4):356–69.CrossRefPubMed

Greenberg SM, Gurol ME, Rosand J, Smith EE. Amyloid angiopathy-related vascular cognitive impairment. Stroke. 2004;35(11 Suppl 1):2616–9.CrossRefPubMed

Durrani R, Wang M, Cox E, Irving E, Saad F, McCreary CR, et al. Mediators of cognitive impairment in cerebral amyloid angiopathy. Int J Stroke. 2023;18(1):78–84.CrossRefPubMed

Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm (Vienna). 2002;109(5–6):813–36.CrossRefPubMed

Chwalisz BK. Cerebral amyloid angiopathy and related inflammatory disorders. J Neurol Sci. 2021;424: 117425.CrossRefPubMed

•• Antolini L, DiFrancesco JC, Zedde M, Basso G, Arighi A, Shima A, et al. Spontaneous ARIA-like events in cerebral amyloid angiopathy-related inflammation: a multicenter prospective longitudinal cohort study. Neurology. 2021;97(18):e1809-e22. The largest published prospective cohort study of inflammatory CAA.

• Grangeon L, Quesney G, Verdalle-Cazes M, Coulette S, Renard D, Wacongne A, et al. Different clinical outcomes between cerebral amyloid angiopathy-related inflammation and non-inflammatory form. J Neurol. 2022;269(9):4972–84. A multicenter retrospective cohort study, the largest such observational study comparing inflammatory CAA outcomes to those of age- and sex-matched controls with non-inflammatory CAA.

•• Theodorou A, Palaiodimou L, Malhotra K, Zompola C, Katsanos AH, Shoamanesh A, et al. Clinical, neuroimaging, and genetic markers in cerebral amyloid angiopathy-related inflammation: a systematic review and meta-analysis. Stroke. 2023;54(1):178–88. A comprehensive systematic review of existing cohort studies and case series, providing our most accurate estimates to date of the prevalence of various clinical, imaging, and genetic biomarkers.

Charidimou A, Boulouis G, Frosch MP, Baron JC, Pasi M, Albucher JF, et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol. 2022;21(8):714–25.

10.

Auriel E, Charidimou A, Gurol ME, Ni J, Van Etten ES, Martinez-Ramirez S, et al. Validation of clinicoradiological criteria for the diagnosis of cerebral amyloid angiopathy-related inflammation. JAMA Neurol. 2016;73(2):197–202.CrossRefPubMed

11.

Salvarani C, Morris JM, Giannini C, Brown RD Jr, Christianson T, Hunder GG. Imaging findings of cerebral amyloid angiopathy, abeta-related angiitis (ABRA), and cerebral amyloid angiopathy-related inflammation: a single-institution 25-year experience. Medicine (Baltimore). 2016;95(20):e3613.CrossRefPubMed

12.

Raghavan P, Looby S, Bourne TD, Wintermark M. Cerebral amyloid angiopathy-related inflammation: a potentially reversible cause of dementia with characteristic imaging findings. J Neuroradiol. 2016;43(1):11–7.CrossRefPubMed

13.

Chung KK, Anderson NE, Hutchinson D, Synek B, Barber PA. Cerebral amyloid angiopathy related inflammation: three case reports and a review. J Neurol Neurosurg Psychiatry. 2011;82(1):20–6.CrossRefPubMed

14.

Wu JJ, Yao M, Ni J. Cerebral amyloid angiopathy-related inflammation: current status and future implications. Chin Med J (Engl). 2021;134(6):646–54.CrossRefPubMed

15.

Corovic A, Kelly S, Markus HS. Cerebral amyloid angiopathy associated with inflammation: a systematic review of clinical and imaging features and outcome. Int J Stroke. 2018;13(3):257–67.CrossRefPubMed

16.

•• Regenhardt RW, Thon JM, Das AS, Thon OR, Charidimou A, Viswanathan A, et al. Association between immunosuppressive treatment and outcomes of cerebral amyloid angiopathy-related inflammation. JAMA Neurol. 2020;77(10):1261–9. A retrospective cohort study providing one of the first systematic investigations of the association between immunosuppression treatments and improved outcomes in inflammatory CAA.

17.

Danve A, Grafe M, Deodhar A. Amyloid beta-related angiitis–a case report and comprehensive review of literature of 94 cases. Semin Arthritis Rheum. 2014;44(1):86–92.CrossRefPubMed

18.

Tabaee Damavandi P, Storti B, Fabin N, Bianchi E, Ferrarese C, DiFrancesco JC. Epilepsy in cerebral amyloid angiopathy: an observational retrospective study of a large population. Epilepsia. 2023;64(2):500–10.CrossRefPubMed

19.

Eng JA, Frosch MP, Choi K, Rebeck GW, Greenberg SM. Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Ann Neurol. 2004;55(2):250–6.CrossRefPubMed

20.

Moussaddy A, Levy A, Strbian D, Sundararajan S, Berthelet F, Lanthier S. Inflammatory cerebral amyloid angiopathy, amyloid-beta-related angiitis, and primary angiitis of the central nervous system: similarities and differences. Stroke. 2015;46(9):e210–3.CrossRefPubMed

21.

Singh B, Lavezo J, Gavito-Higueroa J, Ahmed F, Narasimhan S, Brar S, et al. Updated outlook of cerebral amyloid angiopathy and inflammatory subtypes: pathophysiology, clinical manifestations, diagnosis and management. J Alzheimers Dis Rep. 2022;6(1):627–39.CrossRefPubMedPubMedCentral

22.

Alokley AA, Alshamrani FJ, Alabbas FM, Nazish S. When brain biopsy solves the dilemma of diagnosing atypical cerebral amyoild angiopathy: a case report. Am J Case Rep. 2021;22: e933869.CrossRefPubMedPubMedCentral

23.

Kinnecom C, Lev MH, Wendell L, Smith EE, Rosand J, Frosch MP, et al. Course of cerebral amyloid angiopathy-related inflammation. Neurology. 2007;68(17):1411–6.CrossRefPubMed

24.

Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539–47.CrossRefPubMedPubMedCentral

25.

International CAA and AD Biomarkers International Network. 2023. https://sites.google.com/site/icabinternationalnetwork.

26.

Coulette S, Renard D, Lehmann S, Raposo N, Arquizan C, Charif M, et al. A clinico-radiological study of cerebral amyloid angiopathy-related inflammation. Cerebrovasc Dis. 2019;48(1–2):38–44.CrossRefPubMed

27.

Verbeek MM, Kremer BP, Rikkert MO, Van Domburg PH, Skehan ME, Greenberg SM. Cerebrospinal fluid amyloid beta(40) is decreased in cerebral amyloid angiopathy. Ann Neurol. 2009;66(2):245–9.CrossRefPubMedPubMedCentral

28.

DiFrancesco JC, Brioschi M, Brighina L, Ruffmann C, Saracchi E, Costantino G, et al. Anti-Abeta autoantibodies in the CSF of a patient with CAA-related inflammation: a case report. Neurology. 2011;76(9):842–4.CrossRefPubMed

29.

•• Piazza F, Greenberg SM, Savoiardo M, Gardinetti M, Chiapparini L, Raicher I, et al. Anti-amyloid beta autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies. Ann Neurol. 2013;73(4):449–58. Case series of four patients with inflammatory CAA that demonstrated reduction in anti-Aβ autoantibodies after immunosuppression treatment, which correlated with clinical and radiographic improvement and reduction in microglial activation as measured with ₁₁C-PK11195 PET imaging.

30.

Piazza F, Caminiti SP, Zedde M, Presotto L, DiFrancesco JC, Pascarella R, et al. Association of microglial activation with spontaneous ARIA-E and CSF levels of anti-abeta autoantibodies. Neurology. 2022;99(12):e1265–77.CrossRefPubMedPubMedCentral

31.

Jack CR Jr. Advances in Alzheimer’s disease research over the past two decades. Lancet Neurol. 2022;21(10):866–9.CrossRefPubMed

32.

Leurent C, Goodman JA, Zhang Y, He P, Polimeni JR, Gurol ME, et al. Immunotherapy with ponezumab for probable cerebral amyloid angiopathy. Ann Clin Transl Neurol. 2019;6(4):795–806.CrossRefPubMedPubMedCentral

33.

Greenberg SM, Rosand J, Schneider AT, Creed Pettigrew L, Gandy SE, Rovner B, et al. A phase 2 study of tramiprosate for cerebral amyloid angiopathy. Alzheimer Dis Assoc Disord. 2006;20(4):269–74.CrossRefPubMed

34.

Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, et al. Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 2022;79(1):13–21.CrossRefPubMed

35.

Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7(4):367–85.CrossRefPubMedPubMedCentral

Titel: Diagnosis and Treatment of Inflammatory Cerebral Amyloid Angiopathy
verfasst von: Samuel S. Bruce, MD, MA
Neal S. Parikh, MD, MS
Publikationsdatum: 18.05.2023
Verlag: Springer US
Erschienen in: Current Treatment Options in Neurology / Ausgabe 7/2023
Print ISSN: 1092-8480
Elektronische ISSN: 1534-3138
DOI: https://doi.org/10.1007/s11940-023-00755-6

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Vierten reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen